Just about three weeks since the launch, the BIO Coronavirus Hub now has more than 1,000 users. Here’s an update on our efforts and what our members are doing.
ICYMI: We launched hub.bio.org, a platform for companies to post what information and supplies they need and what they can share, from RNA kits to pipette tips to general information and guidance.
And we’ve redesigned it—to better facilitate collaborations that can accelerate the development of biotech solutions to this crisis.
Hub members can create their own company accounts where they can describe an asset, capacity, or service for which they’re seeking a partner or assistance, or where they can connect with other organizations.
And Hub members can post information in 4 categories:
- Research & Development
- Manufacturing Capacity & Distribution
- Supplies
- General & Scientific Information
To enable a more accurate search, each category has also been divided into sub-topics—and users can add a searchable product type tag, too.
We also have a fantastic partner,Healthcare Ready, who has been matching critically-needed PPE requests with availability.
The impact: “No response has ever gone this fast before,” Phyllis Arthur, BIO’s VP for Infectious Diseases and Diagnostic Policy, told the Los Angeles Times. “We have gone from genetic sequencing to treatment possibilities within weeks.”
For more industry updates, visit www.bio.org/coronavirus or check out these news stories:
More Health Care News:
Bucks County Courier Times: Greenwood on lack of coronavirus preparations
“The federal government was warned the nation was unprepared for an infectious disease pandemic five years ago, says a former Bucks County congressman, now biotech industry lobbyist.”
STAT: You need a special lab to study the coronavirus. Here’s what it takes to get one up and running
“While researchers can more easily study the genetic sequence of the virus or the epidemiology of the pandemic, conducting a full suite of experiments with the actual virus has to be done in laboratories certified as biosafety level 3, or BSL-3.”
The Atlantic: The best hopes for a coronavirus drug
“If there is a way to stop COVID-19, it will be by blocking its proteins from hijacking, suppressing, and evading humans’ cellular machinery.”
The New York Times (Opinion): Congress needs a plan to confront the coronavirus. I have one.
Sen. Elizabeth Warren (D-MA) explains how we can get back to work.
The New York Times (Opinion): Pharmaceutical profits and public health are not incompatible
“We need the capital and creativity of the private sector to take on the coronavirus.”